First Health Pharmaceuticals

30/04/2021

BREAKTHROUGH ACHIEVEMENTS IN HIV CURE:
First Health Pharmaceuticals´ DDX3 inhibiting compound has proved effective against latent HIV infected cells of People Living with HIV according to a study from Erasmus Medical Centre Erasmus MC published today in Nature Communications scientific journal.
Link to the paper👉 https://www.nature.com/articles/s41467-021-22608-z
Link to the news👇 https://www.firsthealthpharma.com/breakthrough-achievements-in-hiv-cure/

Today, the prestigious scientific journal Nature Communications published the article “Selective cell death in HIV-1-infected cells by DDX3 inhibitors leads to depletion of the inducible reservoir”.…

27/02/2021

First Health Pharmaceuticals is thrilled to announce the opening of its new laboratory facilities in Colle di Val d’Elsa – Italy, equipped with proprietary state of the art instruments (the latest spectrometers, advanced automated plate readers and cell counting equipment), which will also operate as a hub for its partners in the life sciences concentration around Siena.

Besides our Research and Development in The Netherlands, First Health Pharmaceuticals has important collaborations worldwide, especially in countries such as India and Italy. Recently we opened new laboratory facilities in Colle di Val d’Elsa – Italy, where we concentrate several of our local R&...

16/12/2019

First Health Pharmaceuticals is hiring!

Interested in joining us? Please have a look at our current vacancies.
����
http://firsthealthpharma.com/were-hiring/

16/12/2019

Our Scientific Director Alessia Tarditi attended the 26th Anatomische Les with Anthony Fauci in Amsterdam. Read more on 👉https://bit.ly/38JsiHB

01/12/2019

It’s ! Let's take a moment to not only draw conclusions on what has been done so far, but also to focus on how much still needs to be done to ending the epidemics and finding a cure for HIV.

It’s World AIDS Day and it’s time to take a moment to not only draw conclusions on what has been done so far, but also to focus on how much still needs to be done to ending the HIV epidemics and finding a cure for HIV. According to the 2018 UNAIDS data, there were approximately …

08/11/2019

First Health Pharmaceuticals participates in 17th European AIDS Conference in Basel, Switzerland on November 6-9, 2019. Read more 👉https://bit.ly/2pWcpvZ

First Health Pharmaceuticals is going to participate in the 17th European AIDS Conference which will be held in Basel, Switzerland, November 6-9, 2019. The European AIDS Conference is a biennial conference which aims to bring together scientists from all over Europe to share the latest research on c...

04/11/2019

First Health Pharmaceuticals is proud to announce a new multi center public-private collaboration on HIV cure research in the Netherlands which focuses on HIV eradication and brings together a unique and innovative combination of research groups from the Erasmus Medical Centre (EMC), Utrecht Medical Centre (UMC), Viiv Healthcare and First Health Pharmaceuticals. The proposal coordinated by Professor Charles Boucher of EMC, encompasses investigative approaches of translational research focusing on the eradication of HIV infected cells as part of a broader HIV cure strategy also known as "Shock and Kill". Read more 👉https://bit.ly/2NcJqg8

Erasmus MC ViiV Healthcare

First Health Pharmaceuticals is proud to announce a new multi center public-private collaboration on HIV cure research in the Netherlands. The project called “Genezingvooriedereenanders” which translates to “A different cure for everyone” focuses on HIV eradication and brings together a uniq...

15/10/2019

First Health Pharmaceuticals will attend the Oncode Institute's workshop on glioblastoma. Find out more about the event 👉https://bit.ly/2MfmsVa

First Health Pharmaceuticals will participate in the workshop organized by Oncode Institute dedicated to glioblastoma. The workshop will be held on October 16th 2019, in Rotterdam, in the Erasmus Medical Center (EMC). Besides presenting current trends on the disease, the Oncode Institute‘s worksho...

10/10/2019

Breast Cancer Awareness Month 🎗:
what’s new in breast cancer research?
Progress made so far in the modulation of the activity of RNA Helicases DDX3 and DDX5, makes inhibition of RNA translation a promising therapeutic strategy.
Find out more about First Health Pharmaceuticals' research strategy: 👉 https://bit.ly/2B2iY21

19/07/2019

First Health Pharmaceuticals’ collaboration with an Oncode Institute-affiliate remarks the importance of fostering cooperation between academia & private companies in a joint effort to improve cancer treatment. 👉🏻 https://bit.ly/2XXi3sI

27/04/2019

Plus Magazine’s take on the importance of prioritizing therapeutics based on low toxicity-compounds, like First Health Pharmaceuticals’ DDX3 RNA Helicase inhibitors. Full article 👉 https://bit.ly/2INLlqD

HIV Plus Magazine

HIV treatment based on low toxicity-compounds, like First Health Pharmaceuticals' DDX3 RNA Helicase inhibitors,should be prioritized in publicly sponsored clinical trials and NIH funded grants.